In short
Clinical trials are investigating Anb032 in people with moderate to severe atopic dermatitis. These studies aim to check whether Anb032 is effective and safe compared with placebo, and they measure skin improvement over time.
Key points
- Clinical trials are investigating Anb032 for moderate to severe atopic dermatitis. Both studies are Phase 2 trials, which means they are checking how well the treatment works while also watching safety. One trial was completed and one was withdrawn. The studies compared Anb032 with placebo and included skin treatments such as hydrocortisone and alclometasone. The main outcomes focused on change in the EASI score and the chance of reaching EASI-75 at Week 14.
Trial overview
The trial data show two Phase 2 studies of Anb032 in people with atopic dermatitis, a long-lasting skin condition also called eczema. Both studies were designed to assess clinical efficacy, which means whether the treatment helps improve the disease, and to compare Anb032 with placebo.
Study design and groups
Both trials were interventional studies, so researchers assigned study treatments and then measured what happened. The study groups included Anb032, placebo, and skin treatments such as hydrocortisone and alclometasone. In one trial, Anb032 was given as a subcutaneous injection, which means an injection under the skin.
Who could participate
The studies were planned for subjects with moderate to severe atopic dermatitis, meaning the skin disease was not mild and could have a bigger effect on daily life. The trial data do not list more detailed entry rules such as age limits or other health conditions.
What was measured
The main outcome in one study was the proportion of subjects who reached EASI-75 at Week 14, which means at least a 75% improvement from the starting skin score. The other study measured the mean change in EASI at Week 14, which shows the average change in eczema severity from the start of the trial. EASI stands for Eczema Area and Severity Index, a score used to track how much skin is affected and how severe it is.
Trial status and size
One Anb032 trial was completed and enrolled 161 subjects. The other trial was withdrawn and had planned enrollment of 160 subjects. These details show that the program included a similar number of participants in both studies, but only one study reached completion.
Patient terms explained
Placebo means a look-alike treatment without the active study drug, used so researchers can compare results fairly. Baseline means the starting point before treatment begins, and Week 14 is the time point used to judge the main results in these studies. Cutaneous use means applied to the skin, while subcutaneous injection means given under the skin.